CLINUVEL PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.21 AUD | +2.01% |
|
+2.36% | -4.94% |
| Apr. 29 | Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3% | MT |
| Mar. 14 | Clinuvel Pharmaceuticals Launches Share Buyback Program | MT |
Evolution of the average Target Price on Clinuvel Pharmaceuticals Limited
Price target over the last 5 years
History of analyst recommendation changes
a97911ce7e4bf68fa3443a1756.eYLft2RJCBYYmbGrOr8dSwMgm2Iat477rxsPfGaKZH0.A_eJ8VUYZEJe4dzSVswuGW1B9RtY88a4mVNcSV7HVxwQ0IfeF3FYfH7NiQ~3711407c5dd41db3d14fcc450bb54c35
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
15.21
AUD
Average target price
25.6
AUD
Spread / Average Target
+68.32%
High Price Target
46.3
AUD
Spread / Highest target
+204.40%
Low Price Target
16
AUD
Spread / Lowest Target
+5.19%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Clinuvel Pharmaceuticals Limited
| Morgans Financial |
Trading Rating
Investor Rating
ESG Refinitiv
C
EPS Revisions
- Stock Market
- Equities
- CUV Stock
- Consensus Clinuvel Pharmaceuticals Limited
